Retained fetal bones following termination of pregnancy mistaken for an intrauterine contraceptive device

Mannampallil Samuel, Usha Kumar, John Parsons, Jackie Ross, Chris Taylor

Case report

A 33-year-old woman of non-UK origin who travelled frequently in her job presented complaining of chronic pelvic pain over the previous 4 years with intermittent exacerbations. The pain was situated mainly in the suprapubic region, was unrelated to her periods or to sexual intercourse and had not been relieved by routine analgesics. She had had two surgical terminations of pregnancy (TOPs), at 14 and 21 weeks’ gestation, 10 years and 8 years previously. She did not disclose the background to these late terminations. She used a combined oral contraceptive pill for contraception for the past 4 years.

Following an acute exacerbation of pain in her home country, the patient had been investigated with an ultrasound scan, which had suggested the presence of an intrauterine device (IUD).

At the family planning clinic a nurse practitioner was unable to see the threads of the supposed IUD and the patient was therefore referred to the clinic dealing with difficult problems in the Department for Sexual and Reproductive Health. She presented a copy of the ultrasound image, which had suggested the presence of an intrauterine contraceptive device (IUD).

Abdominal examination revealed no masses or tenderness. The vulva and vagina looked normal and no IUD thread was seen at the cervical os. Bimanual examination was entirely normal. Given the evidence of the original scan image, the gestation at the second TOP, the patient’s certainty that no intrauterine contraceptive device had then been inserted and the continuing pelvic pain, a further ultrasound scan was performed to clarify the diagnosis. This demonstrated highly echogenic linear structure, although not as straight or regular as would be expected with an IUD, the history and the absence of a thread suggested further investigation.

On gross examination the object removed proved to be flat bone in four or five pieces, each of 1.0–1.2 cm diameter with serrated edges, suggestive of cranial bones. Histology revealed non-viable bone. A repeat ultrasound scan showed complete clearance of the uterine cavity. On follow-up it was apparent that removal of the retained fetal bones had resulted in complete resolution of the chronic pelvic pain.

Discussion

This case presented several unusual features. Retention of fetal bone is a rare complication of abortion and, when it occurs, rarely constitutes a cause of pelvic pain. In the majority of cases described in the literature the discovery of retained fetal bones arises in the course of investigation of reduced fertility, where fetal bone retention is a well-described cause. Other sequelae of retained fetal bones include dysmenorrhoea and dysfunctional uterine bleeding or menorrhagia. The chronic pelvic pain complained of by the patient did not therefore suggest retained fetal bone as a cause.

The case history recorded two TOPs, both after the thirteenth week. Retention of fetal bony fragments most commonly arises after operative second-trimester or late first-trimester TOPs. In later mid-trimester abortions, instrumentation tends to detach the fetal trunk and the skull may have to be crushed as removal of the fetal head may be difficult. The detailed case history is an important attempt to remove the echogenic source under local anaesthesia.

After preparing the patient for examination with aseptic precautions, 2.5 ml prilocaine 3% was injected into the 9 o’clock and 3 o’clock positions of the cervix using a 22-gauge needle. Under ultrasound guidance careful sounding of the uterine cavity revealed a grating sensation. It was therefore probable that the echogenic source was a foreign body (which could have been an IUD or fetal remains) or calcification of intrauterine tissue. Using alligator forceps, a careful attempt was made to remove the object but only partial removal was possible due to the patient’s discomfort. Removal was therefore completed under general anaesthesia with hysteroscopic guidance.

Figure 1 Transvaginal ultrasound scan showing highly echogenic linear structure within the endometrial cavity (photograph courtesy of Dr Jackie Ross)
diagnostic tool given the close link between prior TOP and retained fetal bone. There are other rare causes for the occurrence of bone in the uterus. They include bony metaplasia of the endometrium, osseous heteroplasia, and dystrophic calcification and ossification of the endometrium.6

If the fetal bones had been retained from the patient’s second TOP in 1995 until she presented in 2004, they must have been in situ for 9 years. Long-term retention is unusual but not unknown, with periods of 2.6 to 17 years8 reported in the literature.

Conclusion
Unfamiliar echogenic patterns on ultrasound scans should be scrutinised with care and considered in the light of the patient’s history as possible indications of unusual abnormalities.

Statements on funding and competing interests
Funding None identified.
Competing interests None identified.

Authors’ note
Several unsuccessful attempts were made to contact the patient to secure her consent for publication. The patient’s occupation may mean that she is now resident outside the UK.

References

Not all progestogens are the same

Contraceptive choice she’ll appreciate

Ethinylestradiol and drospirenone

Yasmin®

Indication: Contraception. Further information is available on request from the Marketing Authorisation Holder: Bayer plc., Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA. Legal Category: POM. Further information may be found in the Summary of Product Characteristics. Please read Summary of Product Characteristics before prescribing, particularly in relation to side effects, precautions and contra-indications. Yasmin is a registered trademark of Bayer Schering Pharma AG (formerly Schering AG).

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Bayer Schering Pharma; Tel: 01635 563500, Fax: 01635 563703, E-mail: phdsuk@bayer.co.uk

Date of preparation: May 2009
SYSM74

©FSRH J Fam Plann Reprod Health Care 2009: 35(3)